======= SUZ12 ======= == Gene Information == * **Official Symbol**: SUZ12 * **Official Name**: SUZ12 polycomb repressive complex 2 subunit * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=23512|23512]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q15022|Q15022]] * **Interactions**: [[https://thebiogrid.org/search.php?search=SUZ12&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20SUZ12|Open PubMed]] * **OMIM**: [[https://omim.org/entry/606245|Open OMIM]] == Function Summary == * **Entrez Summary**: This zinc finger gene has been identified at the breakpoints of a recurrent chromosomal translocation reported in endometrial stromal sarcoma. Recombination of these breakpoints results in the fusion of this gene and JAZF1. The protein encoded by this gene contains a zinc finger domain in the C terminus of the coding region. [provided by RefSeq, Jul 2009]. * **UniProt Summary**: Polycomb group (PcG) protein. Component of the PRC2/EED- EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. The PRC2/EED-EZH2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A. {ECO:0000269|PubMed:15225548, ECO:0000269|PubMed:15231737, ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16618801, ECO:0000269|PubMed:17344414, ECO:0000269|PubMed:18285464, ECO:0000269|PubMed:28229514}. |VEFS-Box| |RSC-type complex| |histone methyltransferase activity (H3-K27 specific)| |sex chromatin| |histone methyltransferase activity| |histone H3-K27 methylation| |ESC/E(Z) complex| |negative regulation of G0 to G1 transition| |histone ubiquitination| |regulation of G0 to G1 transition| |protein-DNA complex| |promoter-specific chromatin binding| |methylated histone binding| |chromatin DNA binding| |histone lysine methylation| |negative regulation of gene expression, epigenetic| |peptidyl-lysine methylation| |histone methylation| |protein alkylation| |protein methylation| |regulation of gene expression, epigenetic| |macromolecule methylation| |nuclear body| |methylation| |peptidyl-lysine modification| |negative regulation of cell cycle process| |histone modification| |covalent chromatin modification| |RNA polymerase II proximal promoter sequence-specific DNA binding| |negative regulation of cell cycle| |protein ubiquitination| |chromatin organization| |negative regulation of cell differentiation| |regulation of cell cycle process| |protein modification by small protein conjugation| |nucleolus| |negative regulation of transcription by RNA polymerase II| |peptidyl-amino acid modification| |positive regulation of cell population proliferation| |negative regulation of developmental process| |protein modification by small protein conjugation or removal| |chromosome organization| |regulation of cell cycle| |negative regulation of transcription, DNA-templated| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |negative regulation of RNA metabolic process| |negative regulation of cellular macromolecule biosynthetic process| |RNA binding| |negative regulation of nucleobase-containing compound metabolic process| |negative regulation of macromolecule biosynthetic process| |negative regulation of cellular biosynthetic process| |negative regulation of biosynthetic process| |regulation of cell population proliferation| |negative regulation of gene expression| |regulation of cell differentiation| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp466|Cannabidiol 20μM R08 exp466]]|-2.41| |[[:results:exp468|CB-5083 0.4μM R08 exp468]]|-2.26| |[[:results:exp498|Lead acetate 2000μM R08 exp498 no dilution day6]]|-2.18| |[[:results:exp131|L-74142 5μM R03 exp131]]|-1.97| |[[:results:exp472|CI-1040 9.5μM R08 exp472]]|-1.73| |[[:results:exp78|Pterostilbene 16μM R02 exp78]]|-1.72| |[[:results:exp505|ML-792 0.2μM R08 exp505]]|1.76| |[[:results:exp22|MLN-4924 2μM R00 exp22]]|1.98| |[[:results:exp111|R-DABN 8μM R03 exp111]]|2| |[[:results:exp301|VER-155008 3.9μM R06 exp301]]|2.13| |[[:results:exp443|SNS-032 15μM R08 exp443]]|2.54| |[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|2.63| |[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|2.85| |[[:results:exp21|MLN-4924 0.2μM R00 exp21]]|3.95| ^Gene^Correlation^ |[[:human genes:e:eed|EED]]|0.688| |[[:human genes:e:ezh2|EZH2]]|0.687| Global Fraction of Cell Lines Where Essential: 3/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/25| |breast|2/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|1/15| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/14| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 1501 * **Expression level (log2 read counts)**: 7.45 {{:chemogenomics:nalm6 dist.png?nolink |}}